<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04001504</url>
  </required_header>
  <id_info>
    <org_study_id>VIP-ACS trial</org_study_id>
    <nct_id>NCT04001504</nct_id>
  </id_info>
  <brief_title>Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes</brief_title>
  <acronym>VIP-ACS</acronym>
  <official_title>Evaluation of the Effectiveness of Double Dose Influenza Vaccination to Reduce Major Cardiovascular Events After an Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease has a great burden in the context of public health, as well as the low
      pharmacological adherence of patients who have chronic non-transmissible diseases. However,
      the investigators do not have data on the efficiency of vaccination to reduce cardiovascular
      events in the acute coronary syndromes, and the few studies evaluating the cardioprotective
      potential of the influenza vaccine were conducted in countries with well defined
      seasonalities, divergent of Brazil, that presents a constant viral circulation during all
      months of the year and distinct among its regions. Therefore, study evaluating higher dose
      vaccination in a period that contemplates the seasonality of the influenza virus in Brazil
      may bring important findings to different scientific gaps, as well as clarify questions about
      the possible benefit of doubled vaccination - which does not present contraindications -
      immediately after a atherothrombotic event. If it shows real benefit, it could also be a
      future therapeutic tool adjuvant to traditional drug therapy in the prevention of
      cardiovascular events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III, randomized, controlled, multicenter, open label, superiority, 1:1 allocation,
      blind assessment of clinical outcomes and intention-to-treat analysis clinical trial to
      determine whether increased doses of influenza vaccine in the hospital phase, when compared
      to usual dose vaccination (30 days hospital discharge), reduce the risk of major
      cardiovascular events (cardiovascular mortality, acute myocardial infarction and stroke) in
      patients with acute coronary syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Cardiovascular Events (MACE)</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiovascular mortality, non-fatal myocardial infarction (MI), or non-fatal stroke.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first event (before control group vaccine effect): Cardiovascular mortality, non-fatal myocardial infarction (MI), or non-fatal stroke.</measure>
    <time_frame>45 days</time_frame>
    <description>Index hospitalization discharge to 45 day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-case mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Time to first occurrence of all-cause mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of myocardial revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unstable angina hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of hospitalization due to unstable angina.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of hospitalization due to heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient ischemic attack</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of transient ischemia attack.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of probable and definite stent thrombosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper and lower infection hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of hospitalization due to upper and lower respiratory tract infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal outcome</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as a 30% reduction in the glomerular filtration rate associated with an endpoint of &lt;60 mL / min / 1.73m2 in patients without chronic kidney disease (glomerular filtration rate 60-90 mL / min / 1.73m2) at the beginning of the study. In patients with chronic kidney disease (&lt;60 mL / min / 1.73m2) at the start of the study, renal outcome will be defined as a reduction in glomerular filtration rate or progression of renal disease to stage IV requiring dialysis or kidney transplantation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Solicited injection site and systemic events, unsolicited adverse events and serious adverse events following vaccination.</measure>
    <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
    <description>Occurrence of solicited injection site (Pain, Erythema, Swelling, Induration, and Bruising) and systemic reactions (Fever, Headache, Malaise, Myalgia, and Shivering) will be assessed in all participants.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety overview after influenza vaccination until the end of the study.</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of unsolicited adverse events, including serious adverse events.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">9200</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Double Dose Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double Dose QIV during index ACS hospitalization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Dose QIV 30 days after hospital discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Double Dose Quadrivalent Influenza Vaccine</intervention_name>
    <description>Double Dose QIV (30µg Hemagglutinin)</description>
    <arm_group_label>Double Dose Quadrivalent Influenza Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard Dose Quadrivalent Influenza Vaccine</intervention_name>
    <description>Standard Dose QIV (15µg Hemagglutinin)</description>
    <arm_group_label>Standard Dose Quadrivalent Influenza Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age &gt;= 18 years and older

          -  Acute coronary syndrome in hospital phase.

        Exclusion Criteria:

          -  Participation in another clinical trial with vaccines;

          -  Refusal to provide consent;

          -  Hypersensitivity and/or anaphylaxis to any component of the vaccine, or Guillain-Barré
             within 6 weeks after previous influenza vaccine;

          -  Have already received the influenza vaccine with the same strains used in the study
             within the last 12 months of inclusion in the study

          -  Breastfeeding women;

          -  Pregnant women;

          -  Presenting an acute coronary syndrome during months of December, January, and
             February.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Otávio Berwanger, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academic Research Organization -- Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henrique A Fonseca, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Research Organization -- Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henrique A Fonseca, PhD</last_name>
    <phone>55+ 11 21513725</phone>
    <email>henrique.fonseca@einstein.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vanessa Mazon</last_name>
    <phone>55+ 11 21513725</phone>
    <email>vanessa.mazon@einstein.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto de Cardiologia do Distrito Federal</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenzo Fernandes</last_name>
    </contact>
    <investigator>
      <last_name>Diego M Mesquita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Lucia</name>
      <address>
        <city>Poços De Caldas</city>
        <state>MG</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gislayne Ribeiro</last_name>
    </contact>
    <investigator>
      <last_name>Frederico TC Dall'Orto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ricardo Bergo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pronto Socorro Cardiológico de Pernambuco</name>
      <address>
        <city>Recife</city>
        <state>PE</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarcya Patriota, MSc</last_name>
    </contact>
    <investigator>
      <last_name>Rodrigo P Pedrosa, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodrigo L Patriota, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Estadual de Cardiologia Aloysio de Castro</name>
      <address>
        <city>Rio De Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone R Souza</last_name>
    </contact>
    <investigator>
      <last_name>Aline S Villacorta, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauren P Haeffner</last_name>
    </contact>
    <contact_backup>
      <last_name>Angelica Zanotto</last_name>
    </contact_backup>
    <investigator>
      <last_name>Carisi A Polanczyk, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariana V Vargas, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina de Botucatu - UNESP</name>
      <address>
        <city>Botucatu</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos A Vieira</last_name>
    </contact>
    <contact_backup>
      <last_name>Nelmara Camargo</last_name>
    </contact_backup>
    <investigator>
      <last_name>Marina P Okoshi, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de Marília</name>
      <address>
        <city>Marília</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robson Alves</last_name>
    </contact>
    <investigator>
      <last_name>Pedro B Andrade, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Municipal &quot;Dr. Fernando Mauro Pires da Rocha&quot; - Hospital do Campo Limpo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludimila Souza</last_name>
    </contact>
    <contact_backup>
      <last_name>Lara Ceolin</last_name>
    </contact_backup>
    <investigator>
      <last_name>Vinícus G Vitro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto do Coração - HC FMUSP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natassja Huemer</last_name>
    </contact>
    <contact_backup>
      <last_name>Alexandra Vieira</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jose C Nicolau, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vanessa M Baldo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Talia F Dalçoquio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unstable angina</keyword>
  <keyword>Non-ST-Elevation Myocardial Infarction - NSTEMI</keyword>
  <keyword>ST-Elevation Myocardial Infarction - STEMI</keyword>
  <keyword>Quadrivalent Influenza Vaccine - QIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

